Valuation: Thor Medical

Market Cap 1.7B 184M 165M 152M 138M 257M 17.51B 262M 1.81B 727M 9.21B 692M 677M 29.05B P/E 2026 *
-18.7x
P/E 2027 * -73x
Enterprise Value 1.69B 184M 165M 151M 137M 257M 17.46B 261M 1.81B 725M 9.18B 690M 675M 28.96B EV / Sales 2026 *
89x
EV / Sales 2027 * 11.5x
Free-Float
75.21%
Yield 2026 *
-
Yield 2027 * -
1 day-4.74%
1 week-4.40%
1 month-10.18%
3 months-30.66%
6 months-9.27%
Current year-23.52%
1 week 3.98
Extreme 3.98
4.39
1 month 3.98
Extreme 3.98
4.6
Current year 3.88
Extreme 3.88
7.12
1 year 3.41
Extreme 3.41
7.12
3 years 0.85
Extreme 0.85
7.12
5 years 0.85
Extreme 0.85
7.12
10 years 0.85
Extreme 0.85
7.12
Manager TitleAgeSince
Chief Executive Officer 41 01/08/2024
Director of Finance/CFO 37 01/07/2023
Chief Tech/Sci/R&D Officer - 01/06/2023
Director TitleAgeSince
Director/Board Member 67 28/06/2023
Chairman 59 -
Director/Board Member - 24/04/2025
Date Insider Type Main position Quantity % Market Cap. Importance
26/06/25
Scatec Innovation AS
OthersCompany 31,577,399 10.0434%
18/06/25
Scatec Innovation AS
BuyCompany 3,000,000 0.9542%
02/05/25 Exercice

Director

164,641 0.0524%
Change 5-day change 1-year change 3-year change Capi.($)
-4.74%-4.40%+12.46%+216.14% 184M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.17%+6.34%+44.07%+197.10% 39.45B
Weighted average by Cap. +0.18%+5.44%+47.98%+176.69%

Financials

2026 *2027 *
Net sales 19M 2.07M 1.85M 1.7M 1.54M 2.88M 196M 2.94M 20.29M 8.15M 103M 7.75M 7.59M 325M 143M 15.57M 13.95M 12.83M 11.62M 21.73M 1.48B 22.14M 153M 61.42M 778M 58.45M 57.2M 2.45B
Net income -80.5M -8.75M -7.84M -7.21M -6.53M -12.21M -831M -12.44M -85.98M -34.51M -437M -32.84M -32.15M -1.38B -23.5M -2.55M -2.29M -2.1M -1.91M -3.56M -243M -3.63M -25.1M -10.08M -128M -9.59M -9.38M -402M
Net Debt -5M -544K -487K -448K -406K -758K -51.61M -773K -5.34M -2.14M -27.15M -2.04M -2M -85.62M -43.5M -4.73M -4.24M -3.9M -3.53M -6.6M -449M -6.72M -46.46M -18.65M -236M -17.75M -17.37M -745M
Projected Income Statement - Annual - Thor Medical
Logo Thor Medical
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
Employees
24
Date Price Change Volume
30/10/26 NOK 4.015 -4.74% 4,956,256
29/10/26 NOK 4.215 +1.32% 2,479,108
28/10/26 NOK 4.160 -1.77% 1,431,987
27/10/26 NOK 4.235 +1.93% 3,264,078
26/10/26 NOK 4.155 -1.07% 2,626,007
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.015NOK
Average target price
5.600NOK
Spread / Average Target
+39.48%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Thor Medical
  1. Stock Market
  2. Stocks
  3. NANOV Stock